KARYOPHARM THERAPEUTICS INC
NASDAQ: KPTI (Karyopharm Therapeutics Inc.)
Last update: 17 hours ago1.92
-5.09 (-72.61%)
| Previous Close | 7.01 |
| Open | 2.19 |
| Volume | 22,094,624 |
| Avg. Volume (3M) | 923,288 |
| Market Cap | 43,512,852 |
| Price / Sales | 0.730 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2026 |
| Profit Margin | -43.99% |
| Operating Margin (TTM) | -110.80% |
| Diluted EPS (TTM) | -11.87 |
| Quarterly Revenue Growth (YOY) | -9.40% |
| Current Ratio (MRQ) | 1.33 |
| Operating Cash Flow (TTM) | -122.75 M |
| Levered Free Cash Flow (TTM) | -72.22 M |
| Return on Assets (TTM) | -44.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Karyopharm Therapeutics Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.83 |
|
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.33% |
| % Held by Institutions | 42.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Catalio Capital Management, Lp | 31 Mar 2026 | 897,709 |
| Avidity Partners Management Lp | 31 Mar 2026 | 463,741 |
| Soleus Capital Management, L.P. | 31 Mar 2026 | 440,000 |
| Boxer Capital Management, Llc | 31 Mar 2026 | 302,536 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |